News & Events
< Back to News Overview
Aridol Recommended for Market Authorisation by Adec
13 / 02 / 2006
Specialist pharmaceutical company Pharmaxis Ltd (ASX:PXS, NASDAQ:PXSL) announced today that the Australian Drug Evaluation Committee (ADEC) has recommended to the Therapeutic Goods Administration (TGA) that its first product, AridolT, be registered for sale in Australia.
Alan Robertson, Pharmaxis chief executive officer said: The positive opinion on Aridol from ADEC is great news for people living with asthma. Aridol will soon be available to physicians and respiratory labs treating patients with asthma and it holds out the prospect for better disease outcomes. The concept that has become Aridol was originally conceived by scientists at a Sydney hospital and today's decision represents over ten years of investment by very many people. We look forward to the next phase in the development of Aridol'.
Aridol is designed to identify patients with active airway inflammation such as occurs in asthma, provide information on the severity of their disease, and help monitor the effectiveness of their current treatment. Currently there is no registered, objective test in Australia to confirm the presence or absence of lung inflammation. Asthma is a widespread and chronic condition which has a major impact on public health. In Australia, about 2 million people (10 percent) have clinical symptoms of asthma and worldwide, over 52 million people are affected.
ADEC is appointed by the Federal Minister for Health and Ageing to advise on the suitability of drugs for marketing in Australia. The committee includes eminent physicians, pharmacologists, toxicologists and pharmacists and provides independent, scientific advice on new drugs to the TGA. Its review and subsequent recommendation follows the TGA evaluation of clinical, pharmacological quality and safety data submitted in January 2005, and later consultation with Pharmaxis.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au
SOURCE: Pharmaxis Ltd, Sydney, Australia
CONTACT: Alan Robertson - Chief Executive Officer
Ph: +61 2 9454 7200, Fax +61 2 9451 3622
Alan Robertson, Pharmaxis chief executive officer said: The positive opinion on Aridol from ADEC is great news for people living with asthma. Aridol will soon be available to physicians and respiratory labs treating patients with asthma and it holds out the prospect for better disease outcomes. The concept that has become Aridol was originally conceived by scientists at a Sydney hospital and today's decision represents over ten years of investment by very many people. We look forward to the next phase in the development of Aridol'.
Aridol is designed to identify patients with active airway inflammation such as occurs in asthma, provide information on the severity of their disease, and help monitor the effectiveness of their current treatment. Currently there is no registered, objective test in Australia to confirm the presence or absence of lung inflammation. Asthma is a widespread and chronic condition which has a major impact on public health. In Australia, about 2 million people (10 percent) have clinical symptoms of asthma and worldwide, over 52 million people are affected.
ADEC is appointed by the Federal Minister for Health and Ageing to advise on the suitability of drugs for marketing in Australia. The committee includes eminent physicians, pharmacologists, toxicologists and pharmacists and provides independent, scientific advice on new drugs to the TGA. Its review and subsequent recommendation follows the TGA evaluation of clinical, pharmacological quality and safety data submitted in January 2005, and later consultation with Pharmaxis.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au
SOURCE: Pharmaxis Ltd, Sydney, Australia
CONTACT: Alan Robertson - Chief Executive Officer
Ph: +61 2 9454 7200, Fax +61 2 9451 3622